Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced that it has received confirmation that its application to list the Company's common stock on the NASDAQ Capital Market has been approved by The NASDAQ Stock Market, a unit of the NASDAQ OMX Group. In honor of the listing, Neurotrope will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York City on March 31, 2017. The ceremony will begin at 9:15 a.m. ET. A LiveStream of the NASDAQ Opening Bell will be available at: http://livestream.com/nasdaq/live.
Neurotrope's common stock is expected to begin trading on the NASDAQ Capital Market at the opening of trading on March 29, 2017 under the ticker symbol "NTRP". The Company's common stock will continue to trade on the OTCQB until market close on March 28, 2017 under the ticker symbol "NTRP".
"Listing on the NASDAQ Capital Market is a significant corporate milestone for our company and a testament to the tremendous progress we have made over the past year," stated Dr. Susanne Wilke, CEO of Neurotrope. "We believe that the listing on NASDAQ should help broaden our shareholder base, increase appeal to institutional investors, provide us with better liquidity and, as a result, could ultimately contribute to increasing shareholder value."
Dr. Daniel Alkon, President and Chief Scientific Officer added, "We continue to execute on our clinical and corporate strategy, and anticipate announcing top line efficacy results from our randomized, placebo controlled, Phase 2 study in 148 moderate to severe Alzheimer's dementia patients in April 2017. We are pleased that we will be able to make that announcement as a NASDAQ listed company."
About Neurotrope
Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's dementia and other neurodegenerative diseases. The Company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease.
